Andrea Visentin
A5042091314- Chronic Lymphocytic Leukemia Research
- Lymphoma Diagnosis and Treatment
- Immunodeficiency and Autoimmune Disorders
- Advanced Breast Cancer Therapies
- Chronic Myeloid Leukemia Treatments
- Viral-associated cancers and disorders
- Peripheral Neuropathies and Disorders
- Monoclonal and Polyclonal Antibodies Research
- Galectins and Cancer Biology
- CNS Lymphoma Diagnosis and Treatment
- CAR-T cell therapy research
- PI3K/AKT/mTOR signaling in cancer
- Multiple Myeloma Research and Treatments
- Immune Cell Function and Interaction
- Glycosylation and Glycoproteins Research
- Acute Lymphoblastic Leukemia research
- Cancer Immunotherapy and Biomarkers
- Phagocytosis and Immune Regulation
- Gastrointestinal Tumor Research and Treatment
- Endoplasmic Reticulum Stress and Disease
- Cutaneous lymphoproliferative disorders research
- Acute Myeloid Leukemia Research
- Calcium signaling and nucleotide metabolism
- Blood groups and transfusion
- Cancer Treatment and Pharmacology
University of Padua
2016-2025
Veneto Institute of Molecular Medicine
2014-2023
Istituto Oncologico Veneto
2020-2023
Molecular Oncology (United States)
2020-2023
Azienda Ospedaliera di Padova
2023
University of Pisa
2023
Synlab Czech (Czechia)
2023
University of Cologne
2023
Dana-Farber Cancer Institute
2023
Wilhelminen Hospital
2023
<h3>Objective</h3> To assess whether neuropathy with anti-myelin-associated glycoprotein (MAG) antibody may improve after treatment ibrutinib, an oral inhibitor of Bruton tyrosine kinase, we prospectively treated ibrutinib a cohort 3 patients anti-MAG and Waldenström macroglobulinemia (WM). <h3>Methods</h3> All underwent bone marrow biopsy showing WM, MYD88<sup><i>L265P</i></sup> mutated CXCR4<sup>S338X</sup> wild type, were started on 420 mg/die. Patients assessed at baseline, 3-6-9 months,...
The bone marrow microenvironment promotes proliferation and drug resistance in chronic lymphocytic leukemia (CLL). Although ibrutinib is active CLL, it rarely able to clear leukemic cells protected by mesenchymal stromal (BMSCs) within the niche. We investigated modulation of JAK2/STAT3 pathway CLL BMSCs its targeting with AG490 (JAK2 inhibitor) or Stattic (STAT3 inhibitor). B collected from controls patients, were treated medium alone, ibrutinib, JAK/Signal Transducer Activator...
Complex karyotype (CK) at chronic lymphocytic leukemia (CLL) diagnosis is a negative biomarker of adverse outcome. Since the impact CK and its subtypes, namely type-2 (CK with major structural abnormalities) or high-CK ≥5 chromosome abnormalities), on risk developing Richter syndrome (RS) unknown, we carried out multicenter real-life retrospective study to test prognostic impact. Among 540 CLL patients, 107 harbored diagnosis, 78 were classified as CK2 52 high-CK. Twenty-eight patients...
Neuropathy with antibodies to myelin-associated glycoprotein (MAG) is the most common paraproteinemic IgM neuropathy. Recently, mutational profile of
Abstract In this retrospective international multicenter study, we describe the clinical characteristics and outcomes of patients with chronic lymphocytic leukemia (CLL) related disorders (small lymphoma high‐count monoclonal B lymphocytosis) infected by SARS‐CoV‐2, including development post‐COVID condition. Data from 1540 CLL SARS‐CoV‐2 January 2020 to May 2022 were included in analysis assigned four phases based on cases disposition variants emergence. Post‐COVID condition was defined...
// Valentina Trimarco 1,2,* , Elisa Ave Monica Facco 1,2 Giorgia Chiodin Federica Frezzato Veronica Martini Cristina Gattazzo Lessi 1 Carlo Alberto Giorgi Andrea Visentin Castelli Filippo Severin Renato Zambello Francesco Piazza Gianpietro Semenzato and Livio Trentin Padua University School of Medicine, Department Hematology Clinical Immunology Branch, Padua, Italy 2 Venetian Institute Molecular Medicine (VIMM), * These authors have contributed equally to this manuscript Correspondence to:...
Summary Complex karyotype ( CK ) is a negative prognostic factor in chronic lymphocytic leukaemia CLL ). However, heterogeneous cytogenetic category. Unbalanced rearrangements were present 73·3% of 90 patients with (i.e. ≥3 chromosome aberrations the same clone), and associated shorter overall survival P = 0·025) time to first treatment 0·043) by multivariate analysis. Patients unbalanced presented distinct mRNA expression profile. In conclusion, might represent subset very high‐risk...
Complex karyotype (CK) is a heterogeneous category with negative impact in chronic lymphocytic leukaemia (CLL). Our group has recently reported that CK patients major structural abnormalities (i.e. CK2) are characterised by worse prognosis, as compared to other lesions within CK(CK1).We performed multicentre retrospective study test whether the combination of subtypes IGHV status could be relevant prognostic and predictive tool.Among 522 13% harboured CK2, 41% CK1 and/or U-IGHV (U-CK1) 46%...
7009 Background: The phase 2 CAPTIVATE study evaluated first-line ibrutinib (Ibr) + venetoclax (Ven) for CLL/SLL in cohorts: minimal residual disease (MRD)-guided randomized discontinuation (MRD cohort) and Fixed Duration (FD cohort). Ibr±Ven retreatment was allowed patients (pts) who had progressive (PD). Here, we report outcomes pts with high-risk genomic features from the FD cohort MRD placebo arm. Methods: Pts aged ≤70 y previously untreated without restriction on risk factors received 3...
Considering the role played by heat shock protein of 70 kDa (HSP70) in cancer, we characterized this and its major regulator, factor 1 (HSF1), chronic lymphocytic leukemia (CLL). We found both HSP70 HSF1 overexpressed CLL patients, correlated to poor prognosis abnormally localized nucleus leukemic B cells. The two proteins were strictly each other their levels decreased consensually those patients responding vivo therapeutic regimens. inhibition was proved be effective inducing a...
<h3>Objectives</h3> Ibrutinib is active in anti–myelin-associated glycoprotein (MAG) polyneuropathy with MYD88<sup>L265P</sup> mutation; however, its efficacy likely to be low MYD88 wild-type patients. Venetoclax, an oral inhibitor of BCL2, combination rituximab highly ibrutinib-resistant hematologic malignancies. We report on the first patient anti-MAG and who responded venetoclax-rituximab. <h3>Methods</h3> A 62-year-old woman chronic lymphocytic leukemia had IgM/K neuropathy. She needed...
Not available.
Hairy cell leukemia (HCL) is a rare lymphoproliferative disease with an excellent prognosis after treatment cladribine (2CDA), although relapse may occur during follow-up. The aim of the study to review efficacy, safety, long-term remission rate, and overall survival (OS) in those patients who received 2CDA as first-line treatment. We retrospectively reviewed data HCL treated between March 1991 May 2019 at 18 Italian Hematological centers: 513 were evaluable for purpose. median age was 54...